Latest News - Cencora
Top Corporates Hub
Cencora
Cencora, Inc. (COR) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
08.09.2026 12:25
Cencora, Inc. (COR) Wells Fargo 21st Annual Healthcare Conference September 8, 2026 9:30 AM EDTCompany ParticipantsRobert Mauch - President, CEO &...
RBC Capital Reiterates Sector Perform on Cencora, Maintains $330 Price Target
08.09.2026 10:37
RBC Capital analyst Ryan Halsted reiterates Cencora (NYSE:COR) with a Sector Perform and maintains $330 price target.
Artisan Sold Cencora (COR) as Earnings Momentum Slowed
03.09.2026 13:11
Artisan Partners, an investment management company, released its second-quarter 2026 investor commentary for the “Artisan Global Opportunities Strategy”. The letter can be downloaded here. Global equities rebounded sharply during the quarter, with the MSCI ACWI Index returning 15.3% as resilient economic growth, strong corporate earnings, and continued enthusiasm around artificial intelligence supported markets despite persistent inflation, […]
Cencora’s Accelerate Pharmacy Solutions Launches Cell and Gene Therapy Enablement to Help Health Systems Build and Scale Programs
02.09.2026 13:30
CONSHOHOCKEN, Pa., September 02, 2026--Cencora today launched a service to help health systems evaluate, build and scale cell and gene therapy (CGT) programs. Offered through Accelerate Pharmacy Solutions, Cell and Gene Therapy Enablement is designed to help health systems strengthen operational readiness and program execution to reduce barriers to care and expand patient access to advanced therapies.
RBC Capital Initiates Coverage On Cencora with Sector Perform Rating, Announces Price Target of $330
19.08.2026 09:46
RBC Capital analyst Ryan Halsted initiates coverage on Cencora (NYSE:COR) with a Sector Perform rating and announces Price Target of $330.
5 Insightful Analyst Questions From Cencora’s Q2 Earnings Call
14.08.2026 07:01
Cencora’s second quarter was marked by performance that met Wall Street’s expectations on revenue and exceeded consensus on non-GAAP profitability, driving a positive market response. Management credited execution in specialty pharmaceuticals, especially through its Management Services Organizations (MSOs) like OneOncology and RCA, as a core driver of growth, while digital transformation initiatives improved operational efficiency. CEO Robert Mauch highlighted the company’s unique positioning in
US Stock Market Today: S&P 500 Futures Edge Up As Traders Eye Key CPI
13.08.2026 08:09
The Morning Bull - US Market Morning Update Thursday, Aug, 13 2026 US stock futures are pointing slightly higher this morning, with E-mini S&P 500 contracts up about 0.2% and Nasdaq-100 futures ahead by roughly 0.6%, as investors focus on a key inflation update and what it could mean for interest rates. July CPI is expected at 3.4% year on year, with core inflation seen at 2.5%, which would suggest the cost of living is still rising but closer to the central bank’s comfort zone. At the same...
Camino Announces $5.0 Million Brokered Private Placement of Units and Concurrent $9.5 Million Non-Brokered Private Placement of Convertible Debentures
06.08.2026 11:10
"Not for distribution to United States news wire services or for dissemination in the United States." VANCOUVER, BC / ACCESS Newswire / August 6, 2026 / Camino Minerals Corporation (TSXV:COR)(OTC PINK:CAMZF) ("Camino" or the "Company") is pleased ...
Cencora Q3 Earnings Call Highlights
06.08.2026 11:04
Cencora (NYSE:COR) reported fiscal 2026 third-quarter results marked by double-digit adjusted operating income growth, specialty-business momentum and $1 billion in share repurchases, prompting the pharmaceutical services company to raise its full-year adjusted earnings outlook. Adjusted operating
Evercore ISI Group Maintains Outperform on Cencora, Raises Price Target to $350
06.08.2026 10:57
Evercore ISI Group analyst John Belton maintains Cencora (NYSE:COR) with a Outperform and raises the price target from $330 to $350.
Cencora, Inc. Q3 2026 Earnings Call Summary
06.08.2026 03:04
Moby summary of Cencora, Inc.'s Q3 2026 earnings call
DENTSPLY SIRONA to Post Q2 Earnings: What's in Store for the Stock?
04.08.2026 16:22
XRAY's Q2 results are likely to reflect transformation investments, dealer inventory cuts and weak implants, while Wellspect growth offers support.
Charles River Prepares to Report Q2 Earnings: What's in Store?
30.07.2026 17:29
CRL is set to report Q2 results on Aug. 5 as investors watch segment demand, divestitures, and whether the company can extend its earnings beat streak.
Revvity to Report Q2 Earnings: What's in Store for the Stock?
30.07.2026 16:40
RVTY heads into Q2 earnings with improving Life Sciences demand and resilient Diagnostics. Can stronger margins offset lingering headwinds?
Concentra Group (CON) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
30.07.2026 14:00
Concentra (CON) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The Buyback Machine Hiding Behind Cardinal Health's Thin Margins
27.07.2026 13:54
A steadily shrinking share count and a giant float owed to suppliers are handing owners a bigger slice of the drug distributor each year, even as drug-pricing worries hang over the stock.
Bet on 5 Top-Ranked Stocks With Rising P/E
23.07.2026 12:25
Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach.
2 DiviDog Buys By Barron's Mid-Year Round Table Pros
17.07.2026 05:00
Read here for an update on Barronâs 2026 dividend âdogcatcherâ picksâsafer high-yield stocks, projected gains to 2027, and free-cash-flow red flags.
Cencora (COR) Stock After Recent Pullback And DCF Valuation Gap
29.06.2026 11:07
If you are wondering whether Cencora stock is priced for opportunity or already reflects its strengths, the current setup invites a closer look at what investors are really paying for. Cencora shares last closed at US$286.13, with the stock up 5.5% over the past week and 6.2% over the past month, while still showing a 15.6% decline year to date and a 3.9% decline over the past year. These shorter term moves sit alongside a longer 3 year return of 53.8% and a 5 year return of 158.3%. This...